LI
PVLA

Leap Investments’s Palvella Therapeutics PVLA Stock Holding History

Leap Investments’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-149
Closed -$27K – 589
2020
Q1 		$27K Buy
+149
New +$37.5K 0.04% 347

Other funds holding PVLA

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Leap Investments's PVLA Position: Q2 2020 in Review

Leap Investments sold out of Palvella Therapeutics (PVLA) in Q2 2020, closing a stake of 149 shares — an estimated $27K sold.

Leap Investments first reported a position in PVLA in Q1 2020 and held it in 1 quarter. The position peaked at $27K in Q1 2020. 96 funds tracked by Wall St. Rank hold PVLA as of Q2 2020.

  • Leap Investments reported no remaining Palvella Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Leap Investments sold 149 Palvella Therapeutics shares in Q2 2020, an estimated $27K.
  • Leap Investments first reported a position in Palvella Therapeutics in Q1 2020 and held it in 1 quarter.
  • Leap Investments's Palvella Therapeutics position peaked at $27K in Q1 2020.
  • 96 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.